Vir Biotechnology Beats Q4 Estimates with $64.1M Revenue, $0.31 Loss
Vir Biotechnology posted an adjusted Q4 loss of $0.31 per share versus the $0.42 estimate, beating consensus by 26.9% and improving from a $0.76 loss a year earlier. Quarterly revenue reached $64.07 million, up from $12.37 million year-over-year and 243% above expectations.
1. Q4 Earnings and Revenue
Vir posted an adjusted Q4 loss of $0.31 per share, beating the $0.42 consensus and improving from a $0.76 loss a year earlier, marking a 26.9% EPS surprise. Quarterly revenue reached $64.07 million, up from $12.37 million year-over-year and 243% above expectations.
2. Estimate Surprises and Historical Trend
Prior to this quarter, Vir had posted three straight periods without an EPS or revenue beat; this Q4 marks its first positive surprise on both metrics in four quarters. In the prior quarter, Vir reported a $1.17 loss versus an expected $0.70 loss, representing a 67.1% EPS shortfall.
3. Forward Consensus Outlook and Stock Performance
Consensus forecasts call for Q1 EPS of -$0.60 on $2.41 million revenue and full-year EPS of -$2.94 on $13.28 million, indicating continued unprofitability. Vir shares have risen 25.4% year-to-date compared to a 0.9% gain in the S&P 500.